Compound having lactate transporter activity

A diamondoid cyclic compound facilitates lactate transport across cell membranes, addressing the limitations of existing MCT inhibitor strategies by disrupting lactate gradients in tumors, and when combined with cisplatin, achieves a synergistic anticancer effect, improving treatment outcomes for cancer.

WO2024231590A1PCT designated stage expired Publication Date: 2024-11-14UNIVERSIDAD DE BURGOS +2
View PDF 1 Cites 0 Cited by

Patent Information

Application Number
PCT/ES2024/070286
Authority / Receiving Office
WO · WO
Patent Type
Applications
Current Assignee / Owner
Priority Date
2023-05-11
Filing Date
2024-05-09
Publication Date
2024-11-14

AI Technical Summary

Technical Problem

Current strategies for inhibiting cancer cell growth by targeting lactate transport, primarily through monocarboxylate transporters (MCTs), are limited in effectiveness, particularly in tumors overexpressing MCT1 and MCT4, which are associated with aggressive cancer phenotypes.

Method used

A compound with a diamondoid cyclic system, capable of forming a supramolecular complex with lactate anions, facilitating its transport across cell membranes independently of MCT1 and MCT4, thereby disrupting lactate gradients and exerting a localized cytotoxic effect on tumor cells, potentially combined with cisplatin for enhanced anticancer efficacy.

Benefits of technology

The compound efficiently promotes lactate transport across cell membranes, leading to a localized cytotoxic effect on tumor cells, and when combined with cisplatin, demonstrates a synergistic anticancer effect, reducing the toxicity of cisplatin and enhancing its therapeutic impact.

✦ Generated by Eureka AI based on patent content.

Smart Images

  • Figure ES2024070286_14112024_PF_FP_ABST
    Figure ES2024070286_14112024_PF_FP_ABST
Patent Text Reader

Abstract

The invention relates to a compound of formula (I) or a salt thereof, wherein R1 is selected from a cyclic diamondoid system, a composition comprising the compound, the compound or composition for use thereof as a lactate transmembrane transporter, and a combination comprising the compound and cisplatin for use thereof in the treatment of cancer.
Need to check novelty before this filing date? Find Prior Art

Description

[0001] DESCRIPTION

[0002] Compound that has lactate transport activity

[0003] TECHNICAL SECTOR

[0004] The present invention relates to compounds capable of facilitating the transport of lactate across cell membranes.

[0005] PRIOR STATE OF THE ART

[0006] The lactate anion is a product of the lactic acid fermentation of pyruvate, produced primarily in glycolysis, and is also a mediator of intracellular signaling. Lactate is also a key regulator of cancer development, since overproduction of lactate by cancer cells promotes tumor growth and metastasis. The altered metabolism of tumor cells characterized by increased glycolysis, known as the "Warburg effect," involves the production of large amounts of this metabolite and leads to acidification of the tumor microenvironment (acidosis) and the reversal of the pH gradient found in healthy cells. There is growing evidence indicating that abnormal lactate metabolism constitutes a therapeutic target in cancer. In this regard, two strategies are currently being explored: inhibiting lactate production or altering lactate transport.In the case of the former, it can be achieved by affecting the activity of the enzyme lactate dehydrogenase, which catalyzes the interconversion of pyruvate and lactate. Lactate transport is mediated by proteins known as monocarboxylate transporters (MCTs). Two of them, MCTs 1 and 4, are overexpressed in various types of cancer, such as breast, bone, colon, and kidney cancer. This has also been linked to a worse prognosis in bladder (MCT1) and prostate (MCT4) cancers. Therefore, inhibiting MCT transport activity could lead to the inhibition of cancer cell growth. In this regard, clinical trials (phases I and II) are being conducted with some MCT inhibitors, which prevent the proliferation of cancer cells with aggressive phenotypes. DISCLOSURE OF THE INVENTION.

[0007] The object of the invention is to provide a compound and composition, as defined in the claims.

[0008] One aspect of the invention relates to a compound of formula (I), or a salt thereof, where R1 is selected from a diamond-like cyclic system.

[0009] A second aspect of the invention relates to a composition comprising the compound of the invention.

[0010] A third aspect of the invention relates to a combination comprising the compound of the invention or a pharmaceutically or veterinarily acceptable salt thereof, and cisplatin or a pharmaceutically or veterinarily acceptable salt thereof.

[0011] And a fourth aspect of the invention relates to a non-therapeutic use of the compound as a lactate transporter.

[0012] The compound of the invention has been shown to have lactate anion transport activity across the cell membrane, independently of the natural transporters MCT 1 and 4, and in favor of a gradient. The anionic nature of lactate prevents it from diffusing through lipid membranes. To facilitate this process, the molecule of the invention interacts with the anions through a series of hydrogen bonds, forming a supramolecular complex that can diffuse through said membranes and enter the cell. The molecule of the invention facilitates a localized effect by acting primarily on areas of lactate accumulation caused by the presence of tumor cells, typically in tumor cells of solid tumors, promoting a localized cytotoxic effect in these areas by disrupting the lactate gradients present in the tumor.

[0013] Furthermore, the lactate anion transport activity allows its use in non-therapeutic applications, for example, in experimental trials for research purposes where transmembrane transport of the lactate anion is desired.

[0014] These and other advantages and features of the invention will become apparent in view of the figures and the detailed description of the invention.

[0015] DESCRIPTION OF THE DRAWINGS

[0016] Figure 1 shows a graph representing on the y axis the concentration in pmol / mg extracellular (Fig 1 A) and intracellular (Fig 1 B) of lactate and on the x axis the time in minutes in lung adenocarcinoma (A549) and cervical adenocarcinoma (HeLa) cells treated with a compound, according to an embodiment of the invention.

[0017] Figure 2A shows dose-response curves of the effect on cell viability of cells treated with the same compound as in Figure 1 , with the y-axis representing cell viability in % and the x-axis representing Log (compound) (M); Figure 2B shows the IC50 value (50% inhibitory concentration of the cell population), calculated from the dose-response curves.

[0018] Figure 3A shows a graph of the percentage of cell viability (x-axis) after sensitization of the cell with the compound according to an embodiment of the invention as a pretreatment for 1, 2, 3 and 4 hours, and subsequent treatment with cisplatin for 24 hours. Figure 3B shows a table including results of the synergy analysis of the molecule and cisplatin according to Figure 3A. DETAILED EXPOSURE OF THE INVENTION

[0019] Compound

[0020] A first aspect of the invention relates to a compound of formula (I), or a salt thereof, where R1 is selected from a diamond-type cyclic system.

[0021] In a preferred embodiment, the diamondoid cyclic system is selected from the group consisting of adamantane, diamantane, triamantane, iso-tetramantane, preferably adamantane. Thus, in a preferred embodiment, compound I is a compound with the following formula:

[0022] In a preferred embodiment, the compound of the invention is one of its pharmaceutically acceptable salts or solvates. There are no limitations as to the types of salts that can be used, provided they are pharmaceutically acceptable for therapeutic purposes. In a preferred embodiment, the compound of the invention is preferably a chloride salt. The compound of the invention has demonstrated its ability to efficiently promote transmembrane transport of lactate across phospholipid bilayers in vesicles and its cytotoxic effect on cancer cells, as shown in Example 2.

[0023] The second aspect of the invention relates to a composition comprising the compound of the invention, preferably compound Ia. The compound of the invention is a lactate transporter, and more specifically, a cellular transmembrane lactate transporter, as can be seen in Examples 2 and 3. The composition therefore comprises a lactate transporter, wherein the lactate transporter comprises the compound of the invention.

[0024] In a preferred embodiment, the composition is a pharmaceutical composition comprising the compound of the invention, preferably compound Ia, together with one or more pharmaceutically acceptable excipients or carriers.

[0025] Such pharmaceutical compositions include any solid, semi-solid or liquid composition for oral, topical or parenteral application to the patient.

[0026] The pharmaceutical composition comprises the compound of the invention together with pharmaceutically acceptable excipients or vehicles, in a patient in need of treatment and / or prevention, including humans.

[0027] Those skilled in the art can determine which additional components can be used and whether they are necessary, many of which are commonly used in pharmaceutical compositions.

[0028] Each component must be pharmaceutically acceptable in the sense of being compatible with the other ingredients of the pharmaceutical composition. Uses

[0029] Another aspect of the invention relates to the composition and / or compound of the invention, in its different embodiments, for use as a cellular transmembrane lactate transporter.

[0030] In a preferred embodiment, the invention relates to the composition and / or compound of the invention for use as a medicament or for the treatment or prevention of cancer and / or diseases associated with abnormal lactate transport, wherein the treatment is, at least in part, mediated by lactate transport. In a preferred embodiment, it relates to the treatment of solid tumors, such as lung cancer. The present invention contemplates the treatment of humans, as well as other animals, preferably mammals.

[0031] In another embodiment, the treatment or prevention comprises administering a therapeutically effective amount of the compound or pharmaceutical composition or medicament defined above, together with pharmaceutically acceptable excipients or vehicles, to a subject in need thereof, preferably a subject or patient comprising cancer and / or diseases associated with abnormal lactate transport.

[0032] In the context of the specification, the term "prevention or treatment" means the administration of the compound or pharmaceutical composition or medicament according to the invention to preserve the health of a patient suffering from or at risk of suffering from any of the diseases described above.

[0033] In the context of this invention, the term “therapeutically effective amount” refers to the amount of compound or composition that is sufficient to prevent or treat one or more symptoms derived from the disease to be treated.

[0034] These terms also include the administration of the compound, pharmaceutical composition, or medicament according to the invention to prevent, ameliorate, alleviate, or eliminate one or more symptoms associated with any of these diseases. In the context of this invention, "improvement" means any improvement in the clinical condition of the treated patient, whether a subjective improvement (symptom or how the patient feels) or an objective improvement (sign or measured parameters).

[0035] The particular dose administered in accordance with the present invention will be determined according to the particular circumstances surrounding the case, including the compound administered, the route of administration, the particular condition being treated, and similar considerations.

[0036] In another embodiment, it further comprises administering a therapeutically effective amount of cisplatin. As demonstrated in Example 4, the combination of the compound of the invention and cisplatin produces a synergistic anticancer effect, allowing for a lower dose of cisplatin, with a consequent reduction in its toxicity.

[0037] The combination therapy of the present invention may include the sequential, simultaneous, separate, or combined administration of the compound of the invention and cisplatin. In a preferred embodiment, the treatment comprises first administering the compound of the invention and then administering cisplatin. Without wishing to be bound by any theory, it is hypothesized that the compound of the invention sensitizes the cells to be treated to the chemotherapeutic agent cisplatin, favoring the effect of cisplatin at lower doses than if it were a monotherapy treatment with cisplatin, thus decreasing the toxicity of cisplatin.

[0038] Another aspect of the invention relates to combinations of the compound of the invention with other pharmaceutical or veterinary active ingredients.

[0039] In one embodiment, the combination comprises the compound of the invention, preferably of formula Ia, and if it comprises it in salt form, this salt being pharmaceutically or veterinarily acceptable thereof, and cisplatin or a pharmaceutically or veterinarily acceptable salt thereof, for use in the treatment of cancer in a subject, preferably a cancer that causes solid tumors, wherein the treatment comprises the administration to said subject of an effective amount of the compound of the invention simultaneously, concurrently, separately or sequentially with cisplatin, preferably in a therapeutic interval with cisplatin, that is, wherein the therapeutic effects of the administered compound of the invention have not completely disappeared when cis platinum is administered.

[0040] A final aspect of the invention relates to the non-therapeutic use of the composition and / or compound of the invention as a lactate transporter. The fact that the compound of the invention is a transmembrane lactate transporter makes it suitable as a reagent for use in research where transmembrane lactate transport must be induced or simulated in in vitro assays.

[0041] Some illustrative examples are described below, clearly demonstrating the features and advantages of the invention. However, these examples should not be construed as limiting the scope of the invention as defined in the claims.

[0042] Example 1: Synthesis of compound la (AS37)

[0043] A mixture of 5-(1-(4-(tert-butyl)phenyl)-1 / 7-1,2,3-thazol-4-yl)-3-methoxy-1 / 7-pyrrole-2-carbaldehyde (120 mg, 0.37 mmol), 1-adamantylamine (112 mg, 0.74 mmol, 2.0 equiv) and glacial acetic acid (100 µL) in chloroform (15 mL) was stirred at 65 °C for 72 h. After cooling to room temperature, the solvent was removed under reduced pressure and the residue was redissolved in dichloromethane (25 mL). This solution was washed with 1 M aqueous HCl solution (3 x 25 mL); the organic phase was dried over anhydrous sodium sulfate, filtered and the solvent was removed under reduced pressure. The residue was recrystallized from a mixture of dichloromethane and n-hexane to obtain compound AS37 as a brown solid (116 mg, 64%).

[0044] Example 2: Transporter activity of compound la

[0045] On the one hand, the activity of the compound AS37 to coordinate anions was analyzed by testing them in phospholipid vesicle models, demonstrating that they were efficient in facilitating lactate transport at very low concentrations (Table 1). Table 1. Transport activity expressed as the concentration necessary to facilitate the transport of 50% of the encapsulated anion EC50 (nM) and Hill parameter (n) for AS37.

[0046] CEso Parameter of CEso Parameter of CEso Parameter

[0047] Compound (nM) Hill, (nM) Hill, (nM) Hill,

[0048] NO3- / CI- n NO3- / CI- HCO3- / CI- n HCO3- / CI- lac- / C|- n lac" / CI"

[0049] AS37 3.7 + 0.4 0.91 + 0.08 39 + 2 0.97 + 0.06 8 + 1 1.0 + 0.1

[0050] The ability of AS37 to transport the lactate anion across cellular membranes was evaluated in two cancer cell lines (A549 and HeLa). These cells were treated with the compound at a concentration equivalent to their respective 25% inhibitory concentrations (IC25) of the cell population, obtained from cell viability assays. Using a luminescence-based method (Lactate-Glo™ Assay Kit, Promega, Wl, USA), extracellular (Figure 1A) and intracellular (Figure 1B) lactate concentrations were determined under different conditions and treatment times. Under regular culture conditions and with a glucose-rich medium, cancer cells export lactate (mainly produced by glycolysis) to the extracellular matrix via monocarboxylate transporters (MCTs).For this reason and in order to accurately evaluate the transport capacity of the compound of the invention, in these cellular models the different isoforms of the MCTs (MCT1 and MCT4) were pharmacologically inhibited using Syrosingopine (Syro) as a pre-treatment (incubation for 1 hour at a dose of 10 pM for both cell lines).

[0051] A549 and HeLa cells were treated with 2.3 pM and 2.8 pM of the compound of the invention, respectively, and all experimental cultures were done in a lactate-free medium.

[0052] Extracellular lactate levels in both cell lines treated with Syro were lower than in the case of the control (DMSO), with significant differences being found after 180 minutes (p<0.01 and p<0.001, for A549 and Hela respectively). These results confirm that Syro is capable of reducing lactate accumulation in the extracellular medium mediated by the inhibition of MCTs. Experiments with the compound of the invention in both cancer cell lines showed an increase in extracellular lactate concentrations compared to the control, however, there were only significant differences in A549 cells after 180 minutes of treatment (p<0.0001). Finally, in the case of combined treatment with Syro and AS37 (inhibited MCTs), significantly higher extracellular lactate concentrations were observed in A549 cells compared to Syro at 60, 120 and 180 minutes (p<0.05, p<0.01 and p<0.0001, respectively).In the case of HeLa cells, these differences were found only at 120 (p<0.05) and 180 (p<0.0001) minutes of treatment.

[0053] Regarding intracellular lactate levels, in both cancer cell lines it was observed that after being treated with Syro the concentrations were significantly higher compared to the control (DMSO) between 15 and 180 minutes of treatment (p<0.0001), confirming that Syro is capable of inhibiting MCTs and, consequently, inducing intracellular lactate accumulation. Regarding treatment with AS37, in HeLa cells the intracellular lactate levels were lower compared to those of the control, but without significant differences, while in A549 cells the concentrations were slightly higher than the control with significant differences at 60 (p<0.01), 120 (p<0.05) and 180 minutes (p<0.05) of treatment.Finally, intracellular lactate levels in A549 and HeLa cells treated with Syro and AS37 combined were significantly lower than those in cells treated with Syro alone at 120 (p<0.05 and p<0.0001, for A549 and HeLa, respectively) and 180 minutes (p<0.0001, for both cell lines) of treatment, but were always higher than those in cells treated with AS37 alone or with controls (DMSO). These results indicate that AS37 is able to increase extracellular lactate concentrations through a mechanism independent of MCT activity. Furthermore, AS37 is able to reduce intracellular lactate accumulation, a characteristic observed as a result of MCT inhibition, indicating equivalent activity in facilitating lactate efflux from the cell interior.

[0054] Example 3: Cytotoxic effect of compound AS37

[0055] The effect of AS37 on cancer cell viability was evaluated in the human cell lines A549 (lung adenocarcinoma), SW900 (lung squamous cell carcinoma), MCF7 (breast adenocarcinoma), CAL27 (oral cavity squamous cell carcinoma), SW620 (colorectal adenocarcinoma), and HeLa (cervical adenocarcinoma). Furthermore, its cytotoxic potential was also evaluated in the non-cancerous cell line MCF10A (non-cancerous breast epithelium). Using statistical software, cell viability percentages were graphed with a dose-response curve, and inhibitory concentrations (Cl) were calculated for 25%, 50%, and 75% cell viability. The Cl values ​​for each cell line are shown in Table 2, and their respective dose-response curves are shown in Figure 2A.

[0056] Table 2. AS37 Cl in different cancer and non-cancer cell lines. Values ​​represent the mean and standard deviation (in pM) of at least three independent replicates.

[0057] A549 SW900 MCF7 CAL27 SW620 HeLa MCF10A

[0058] IQ75 4.92 + 1.09 5.57 + 0.59 7.91 + 1.42 4.00 + 0.50 3.70 + 0.39 3.95 + 0.26 11.22 + 3.94

[0059] Clso 3.35 + 0.87 4.36 + 0.27 5.58 + 1.17 3.27 + 0.27 2.14 + 0.32 3.36 + 0.19 7.66 + 1.86

[0060] IQ25 2.30 + 0.71 3.43 + 0.06 4.00 + 1.22 2.68 + 0.18 1.26 + 0.35 2.85 + 0.16 5.36 + 1.09

[0061] In all cell lines, AS37 induced a pronounced reduction in cell viability with a therapeutic range below approximately 10 pM. When comparing IC50s, among cancer cell lines MCF7 was significantly more resistant than A549 (p<0.01), CAL27 (p<0.001), SW620 (p<0.0001), and HeLa (p<0.05) cells (Figure 2B). On the other hand, the non-cancer cell line (MCF10A) was significantly more resistant than all cancer cell lines; A549, SW900, CAL27, SW620, HeLa (p<0.0001), and MCF7 (p<0.01) cells (Figure 2B). Finally, SW620 cells were significantly more sensitive (with lower IC50 values) than SW900 (p<0.05), MCF7 (p<0.0001) and MCF10A (p<0.0001) cells (Figure 2B).

[0062] The meaning of the symbols in Figure 2B is as follows: tp<0.05, tt p<0.01, p<0.001 and tttt p<0.0001 indicate significant differences with respect to the MCF7 cell line;

[0063] ** p<0.01 and **** p<0.0001 indicates significant differences with respect to the MCF10A cell line.

[0064] * p<0.05 indicates significant differences with respect to the SW620 cell line.

[0065] Example 4: Synergistic effect of AS37 and Cisplatin

[0066] The efficacy of compound AS37 as a pretreatment in sensitizing A549 cells to the chemotherapeutic agent cisplatin was tested using a cell viability MTT assay. Because lactate anion transport across the cell membrane has been demonstrated over short periods of time, the effect of the combination with cisplatin was evaluated after pretreatment for 1, 2, 3, and 4 hours with a dose of 3.4 pM (IC50) of AS37 (blocks BB in Figure 3A). After this pretreatment, cells received a dose of 100 pM cisplatin for an additional 24 hours. The results show that the combined effect of the therapy exceeds the individual effect of each compound (blocks AA in Figure 3A), observing a greater effect when the cells receive pre-treatment with compound AS37 for 4 hours (p < 0.0001, Figure 3A).Taking these results into account, a detailed analysis of the therapeutic synergy between the two drugs was performed. The cell viability percentages obtained after the combination of the drugs were analyzed with the CompuSyn software (version 1.0; ComboSyn, Paramus, NJ, USA) to calculate the combination index (ICo). The ICo is used to describe the type of interaction between drugs, which can be synergistic (0.30 > ICo < 0.70), moderate synergy (0.70 > ICo < 0.85), mild synergy (0.85 > ICo < 0.90), additive effect (0.9 > ICo < 1.1) or antagonistic effect (ICo > 1.1).

[0067] In this assay, A549 cells were pre-treated for 4 hours with different doses of compound AS37 (2.3, 3.4, and 4.9 pM). After pre-treatment, cells were treated with cisplatin using different doses (50, 100, 150, 200, and 250 pM) for an additional 24 hours. As shown in Figure 3B, in all combinations the ICo value was less than 0.915 (Figure 3B), indicating that treatment with both drugs in this modality has a mainly moderate to mild synergistic effect. Notably, the greatest synergistic effect was observed when combining the lowest doses of both drugs.

Claims

CLAIMS a compound of formula (I), or a salt thereof, where R1 is selected from a diamond-like cyclic system.

2. The compound according to claim 1, wherein the compound (I) is a compound of formula (Ia):

3. A composition comprising the compound according to any of the preceding claims.

4. The composition according to claim 3, comprising one or more pharmaceutically acceptable excipients or carriers.

5. The compound according to any of claims 1 or 2 or the composition according to any of claims 3 or 4, for use as a transmembrane lactate transporter.

6. The compound according to any of claims 1 or 2 or the composition according to any of claims 3 or 4, for use in the treatment of a disease mediated by lactate transport.

7. The compound or composition according to claim 6, wherein the disease is cancer.

8. The compound or composition according to claim 7, wherein the cancer is lung cancer.

9. The compound or composition according to any one of claims 6 to 8, for use in the treatment comprising administering an effective amount of the compound or composition to a subject comprising cancer and / or diseases associated with abnormal lactate transport.

10. The compound or composition according to claim 9, for use in the treatment comprising administering to said subject an effective amount of a compound or composition comprising cisplatin.

11. A combination comprising: a) a compound according to any of claims 1 or 2, or a pharmaceutically or veterinarily acceptable salt thereof, and b) cisplatin or a pharmaceutically or veterinarily acceptable salt thereof.

12. The combination according to claim 11 for use in the treatment of cancer of a subject, preferably a cancer that causes solid tumors, wherein the treatment comprises administering to said subject an effective amount of the compound of formula (I) simultaneously, concurrently, separately or sequentially with cisplatin.

13. Non-therapeutic use of the compound according to any of claims 1 or 2 as a lactate transporter.

Citation Information

Patent Citations

  • 2-(1,2,3-triazo-4-YL)-pyrrole derivatives having ionophoric activity

    WO2020192904A1